Los Angeles, CA -- (SBWIRE) -- 05/20/2019 -- This study researches the market size of Drugs for Herpes Labialis (Oral Herpes), presents the global Drugs for Herpes Labialis (Oral Herpes) sales and revenue by companies, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.
This report focuses on the key data information of Drugs for Herpes Labialis (Oral Herpes) in key regions like North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa, presents sales, revenue, market share, growth rate of Drugs for Herpes Labialis (Oral Herpes) for each region and countries in each region.
For top companies, this report investigates and analyzes the sales, revenue, market share and growth rate for the top players, key data from 2013 to 2018.
This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.
Get PDF template of this report: https://www.qyresearch.com/sample-form/form/720028/global-drugs-for-herpes-labialis-oral-herpes-industry-research-report-growth-trends-and-competitive-analysis-
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US.
The classification of drugs for herpes labialis (oral herpes) includes valacyclovir, aciclovir, famciclovir, docosanol and other. The proportion of aciclovir in 2016 is about 17%, and the proportion of valacyclovir is about 45%.
Drugs for herpes labialis (oral herpes) are widely used though external use, oral and injection. The most proportion of drugs for herpes labialis (oral herpes) is oral, and the consumption in 2016 is about 1200 M USD.
North America is the largest consumption place, with a revenue market share nearly 36.5% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 28.4%.
Market competition is intense. GSK, Novartis, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
In 2018, the global Drugs for Herpes Labialis (Oral Herpes) market size was 2040 million US$ and is forecast to 3030 million US in 2025, growing at a CAGR of 5.1% from 2018. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Drugs for Herpes Labialis (Oral Herpes).
This report includes the following manufacturers; we can also add the other companies as you want.
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun Group
Hikma
Haiwang
Carmex
Cipher
Market Segment by Product Type
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Market Segment by Application
External Use
Oral
Injection
Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Egypt
South Africa
Get Full Report Now at USD 3,550 @ https://www.qyresearch.com/settlement/pre/9321f588b71ea8b659edef423673363a,0,1,Global%20Drugs%20for%20Herpes%20Labialis%20(Oral%20Herpes)%20Industry%20Research%20Report,%20Growth%20Trends%20and%20Competitive%20Analysis%202018-2025
About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.